The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma
暂无分享,去创建一个
P. Moreau | H. Avet-Loiseau | X. Leleu | G. Marit | J. Corre | T. Facon | M. Attal | B. Royer | L. Lodé | P. Rodon | L. Garderet | O. Fitoussi | L. Karlin | A. Stoppa | P. Lenain | E. Voog | O. Allangba | M. Wetterwald | C. Hulin | D. Caillot | M. Maigre | L. Voillat | L. Legros | B. Hébraud | M. Dib | marie-Veronique Joubert | B. Kolb | N. Daguindau | C. Sohn | N. Boullanger
[1] N. Munshi,et al. Minor clone provides a reservoir for relapse in multiple myeloma , 2013, Leukemia.
[2] J. Carpten,et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. , 2012, Blood.
[3] J. Carpten,et al. Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.
[4] G. Morgan,et al. The genetic architecture of multiple myeloma , 2012, Nature Reviews Cancer.
[5] A. Kenneth,et al. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] P. Sonneveld,et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. , 2010, Blood.
[7] B. Barlogie,et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.
[8] B. Barlogie,et al. The molecular characterization and clinical management of multiple myeloma in the post-genome era , 2009, Leukemia.
[9] L. Staudt,et al. IRF4 addiction in multiple myeloma , 2008, Nature.
[10] John D. Shaughnessy,et al. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. , 2008, Blood.
[11] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.
[12] Yongsheng Huang,et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.
[13] Bart Barlogie,et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.
[14] P. L. Bergsagel,et al. Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.
[15] L. Baldini,et al. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. , 2000, Cancer research.